Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reshma Kewalramani
Pharma
Don't pigeonhole Vertex as a rare disease company, execs say
“I think there is a bit of a misconception about us as a company that we’re a rare or an orphan [disease] company,” Vertex's COO said Thursday.
Fraiser Kansteiner
May 6, 2022 7:55am
Vertex's CEO scored a major pay bump in 2021
Apr 8, 2022 11:10am
Vertex aims Trikafta at wider pool of cystic fibrosis patients
Jan 10, 2022 10:45am
Vertex CEO collects $9.1M in pay for 2020, less than her peers
Apr 9, 2021 11:06am
Vertex’s CF drug Trikafta shines but analysts bemoan pipeline
Feb 2, 2021 10:58am
ICER clears Vertex's Trikafta but blasts 'monopoly' pricing
Sep 23, 2020 11:14am